Natixis Advisors LLC raised its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 25.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,917,548 shares of the company's stock after purchasing an additional 390,156 shares during the period. Natixis Advisors LLC's holdings in Haleon were worth $19,731,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Bartlett & CO. Wealth Management LLC grew its position in Haleon by 135.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock worth $27,000 after acquiring an additional 1,491 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in Haleon during the first quarter valued at approximately $29,000. FIL Ltd grew its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the period. Continuum Advisory LLC raised its holdings in Haleon by 152.4% during the 1st quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock worth $49,000 after buying an additional 2,870 shares during the period. Finally, Alpine Bank Wealth Management bought a new stake in shares of Haleon in the first quarter valued at about $56,000. 6.67% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on HLN shares. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Barclays restated an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Finally, Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective for the company in a research note on Friday, May 9th. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $12.33.
Get Our Latest Research Report on HLN
Haleon Trading Up 2.3%
Shares of NYSE:HLN traded up $0.22 during trading on Thursday, reaching $9.47. The stock had a trading volume of 15,726,060 shares, compared to its average volume of 13,246,037. The stock has a market cap of $42.52 billion, a price-to-earnings ratio of 24.27, a P/E/G ratio of 2.71 and a beta of 0.23. The firm's fifty day moving average is $10.26 and its 200 day moving average is $10.19. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.78 and a current ratio of 0.87. Haleon PLC Sponsored ADR has a 52 week low of $8.86 and a 52 week high of $11.42.
Haleon Increases Dividend
The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 18th. Stockholders of record on Friday, August 15th will be given a dividend of $0.0555 per share. The ex-dividend date of this dividend is Friday, August 15th. This is a positive change from Haleon's previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. Haleon's payout ratio is currently 64.10%.
Haleon Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Read More

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.